Published in Mol Cancer on August 29, 2013
A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler (2014) 0.95
Targeting Rho-GTPases in immune cell migration and inflammation. Br J Pharmacol (2014) 0.85
Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol (2015) 0.81
Unfolding the Role of Large Heat Shock Proteins: New Insights and Therapeutic Implications. Front Immunol (2016) 0.80
HMGN2, a new anti-tumor effector molecule of CD8⁺ T cells. Mol Cancer (2014) 0.76
Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports. Sarcoma (2015) 0.75
Kaposi's sarcoma concurrent with granulomatosis polyangiitis. Eur J Rheumatol (2015) 0.75
Psoriasis and Atopic Dermatitis. Dermatol Ther (Heidelb) (2017) 0.75
Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. Medicine (Baltimore) (2016) 0.75
Hinokitiol Negatively Regulates Immune Responses through Cell Cycle Arrest in Concanavalin A-Activated Lymphocytes. Evid Based Complement Alternat Med (2015) 0.75
Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol (2017) 0.75
Uveitic macular edema. Eye (Lond) (2016) 0.75
Pathways of tumor development and progression in drug-induced nonmelanoma skin cancer: a new hope or the next great confusion? Wien Med Wochenschr (2014) 0.75
Cancer-related inflammation. Nature (2008) 34.21
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology (2004) 14.78
Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med (1997) 14.51
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Psoriasis. N Engl J Med (2009) 8.80
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev (2012) 5.77
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum (2006) 5.03
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2007) 5.02
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer (2001) 4.61
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol (2009) 4.53
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 3.86
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 3.63
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum (2007) 3.16
Anti-inflammatory Agents: Present and Future. Cell (2010) 3.13
Cancer: Inflaming metastasis. Nature (2009) 3.09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum (2009) 2.97
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther (2008) 2.87
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 2.80
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis (2008) 2.61
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis (2008) 2.36
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer (2008) 2.24
TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist (2006) 2.17
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15
Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA (2012) 2.13
Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther (2006) 2.12
The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum (2007) 2.10
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol (2007) 2.05
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis (2011) 1.99
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf (2010) 1.95
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol (2003) 1.91
TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell (2008) 1.91
TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci (2011) 1.84
Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst (2012) 1.84
Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol (2012) 1.71
Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut (2005) 1.70
Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci (2010) 1.70
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc (2002) 1.65
Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut (2004) 1.63
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol (2011) 1.59
Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer (2006) 1.58
Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol (2006) 1.57
Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis (2008) 1.56
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther (2010) 1.55
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2010) 1.44
Immunological surveillance in neoplasia. Transplant Rev (1971) 1.44
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol (2010) 1.42
The risk of malignancy associated with psoriasis. Arch Dermatol (2001) 1.42
Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum (2008) 1.39
Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther (2007) 1.35
The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology (1999) 1.31
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis (2009) 1.30
Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol (2009) 1.29
Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol (2009) 1.28
Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol (2003) 1.28
Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer (2010) 1.25
Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica (2010) 1.25
Incidence of cancer among patients with systemic sclerosis. Cancer (1995) 1.25
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol (2012) 1.24
Diabetes and pancreatic cancer: chicken or egg? Pancreas (2011) 1.23
Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol (2010) 1.21
Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol (2001) 1.19
Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev (2010) 1.16
Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol (2010) 1.16
Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol (2000) 1.15
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis (2008) 1.12
Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer (2011) 1.11
Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer (2007) 1.11
Intestinal cancer risk in Crohn's disease: a meta-analysis. J Gastrointest Surg (2010) 1.10
Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology (2010) 1.10
Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother (2007) 1.10
Cancer risks in Crohn disease patients. Ann Oncol (2008) 1.10
Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol (2010) 1.08
Delayed diagnosis of coeliac disease increases cancer risk. BMC Gastroenterol (2007) 1.07
Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol (2008) 1.06
TNFalpha -308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls. Breast Cancer Res Treat (2009) 1.05
Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther (2010) 1.03
Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol (2011) 1.03
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) (2010) 1.03
Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci (2011) 1.02
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature (2008) 10.15
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol (2012) 4.47
Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis (2002) 4.13
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 3.90
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol (2010) 3.88
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A (2009) 3.31
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08
Clinical practice. Dysplastic nevi. N Engl J Med (2003) 2.99
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol (2002) 2.94
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis (2007) 2.89
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol (2009) 2.88
Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem (2002) 2.73
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet (2008) 2.67
NetPath: a public resource of curated signal transduction pathways. Genome Biol (2010) 2.62
IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol (2007) 2.60
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem (2004) 2.55
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis (2012) 2.55
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53
Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog (2008) 2.38
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis (2009) 2.33
Cancers complicating inflammatory bowel disease. N Engl J Med (2015) 2.33
IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol (2002) 2.32
Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res (2002) 2.31
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology (2009) 2.26
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Biological therapies for inflammatory bowel diseases. Gastroenterology (2009) 2.18
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut (2012) 2.17
An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet (2007) 2.14
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol (2008) 2.06
Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. Surg Endosc (2012) 2.04
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology (2009) 2.00
Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology (2004) 1.97
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther (2005) 1.96
IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol (2011) 1.92
C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.92
Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut (2010) 1.87
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis (2007) 1.85
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol (2009) 1.82
Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med (2011) 1.78
Predicting the response to infliximab from trough serum levels. Gut (2010) 1.76
IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med (2013) 1.75
Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. Clin Chem Lab Med (2013) 1.75
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2005) 1.73
Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology (2010) 1.73
Characterization of the murine alpha interferon gene family. J Virol (2004) 1.72
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum (2009) 1.70
Management of inflammatory bowel disease in pregnancy. J Crohns Colitis (2012) 1.69
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology (2007) 1.64
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut (2007) 1.64
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut (2007) 1.62
Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol (2003) 1.62
Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum (2006) 1.62
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol (2013) 1.59
Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery (2010) 1.56
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology (2002) 1.55
Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem (2004) 1.53
Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res (2003) 1.53
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut (2010) 1.53
Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther (2005) 1.52
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology (2003) 1.52
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut (2011) 1.52
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol (2012) 1.52
Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol (2008) 1.52
Factors affecting outcomes in Crohn's disease over 15 years. Gut (2012) 1.52
In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res (2011) 1.50
Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol (2013) 1.50
IL-9 promotes IL-13-dependent paneth cell hyperplasia and up-regulation of innate immunity mediators in intestinal mucosa. J Immunol (2009) 1.48
Predictors of severe Crohn's disease. Scand J Gastroenterol (2008) 1.47
Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol (2007) 1.46
IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol (2007) 1.44
The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J Immunol (2009) 1.44